Clinical Trials on Unresectable HER2-Positive Breast Carcinoma in United Kingdom

Total 2119 results

National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
University of Washington
Breast Cancer Research Foundation

Not yet recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...

United States
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression

United States
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Breast Adenocarcinoma | HER2-Positive Breast Carcinoma

United States
Mersana Therapeutics

Recruiting

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive

United States
King's College London
Guy's and St Thomas' NHS Foundation Trust; Brighton and Sussex University Hospitals...

Recruiting

A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies (HERdi PREDICT)

HER2-positive Breast Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

Imaging With a New Agent That Finds a Cancer Protein Called HER2

HER2-positive Carcinoma | HER2-positive Primary Malignancy

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Active, not recruiting

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
University of Arizona
Pfizer

Completed

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1)

Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer Stage

United States
Imperial College London
Medical Research Council; ECMC

Recruiting

D4 Choline Breast PET/CT

Metastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer

United Kingdom
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
Laura Huppert, MD, BA
Ambrx, Inc.

Not yet recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

United States
University of Alabama at Birmingham
Tesaro, Inc.; Susan G. Komen Breast Cancer Foundation; Translational Breast Cancer... and other collaborators

Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Metastatic Breast Cancer | HER2 Positive Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

HER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid Tumor

China, Australia, United States
Enliven Therapeutics

Recruiting

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Colorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid Tumors

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
Veana Therapeutics
University of Washington

Recruiting

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma | Refractory Breast Carcinoma

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Case Comprehensive Cancer Center

Withdrawn

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Stage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Olema Pharmaceuticals, Inc.

Active, not recruiting

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

United States, Australia
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Active, not recruiting

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Breast Cancer, Male | HER2-positive Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Residual Disease | HER2 Positive Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Stage IV Breast Cancer | Invasive Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative...

United States
Clovis Oncology, Inc.

Terminated

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ER

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
Filipa Lynce, MD
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI)

Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma

United States
University of Washington
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Completed

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Stage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu Positive

United States
Ruth O'Regan
University of Rochester; Puma Biotechnology, Inc.

Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Advanced HER2-positive Breast Cancer

France, Italy, Germany, Singapore, Sweden, Spain, United Kingdom, United States

Clinical Trials on Unresectable HER2-Positive Breast Carcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations